 NEWTON, Mass., June 24, 2021 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq:KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC HCR for up to 100 million in new financing to support the ongoing development and commercialization of XPOVIO selinexor, the Companys first-in-class, oral Selective Inhibitor of Nuclear Export SINE compound, and for the clinical development of Karyopharms other programs, including eltanexor. 